Another TIGIT update from Arcus leaves analysts reading the tea leaves — and the big reveal is finally near

Once again, anyone who’s looking for positive signals in Arcus’ latest slice of TIGIT data will have to take the biotech’s word for it.

Arcus opened its Q1 results with an update about its third interim analysis for the ARC-7 study, a Phase II trial comparing three different regimens: a...

Click to view original post